Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
Sina Rashedi, Postdoctoral Research Fellow at Brigham and Women’s Hospital, Harvard Medical School, shared a post on X:
”Honored to be a part of the HI-PRO trial, presented today by my mentor Gregory Piazza at ESC Congress 2025
Published in NEJM.
In provoked VTE and enduring risk,
Extended low-dose apixaban vs placebo:
Decreased risk of recurrent VTE with low risk of major.”
Read the full article here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Oct 21, 2026, 18:13Wolfgang Miesbach: Hereditary Hemorrhagic Telangiectasia An Overlooked Bleeding Disorder
-
Oct 21, 2026, 17:55Gayatri Kotwal։ New Review on Anemia, Pain, and Nutritional Deficiencies in Cancer Patients
-
Oct 21, 2026, 17:40Tetsuzan Ron: Iron Deficiency Without Anemia Clinical Impact and Management
-
Oct 21, 2026, 17:29Amir Hossien Esfandiari։ The Association Between Viral Infections and Aplastic Anemia
-
Oct 21, 2026, 17:16Melissa Hollo: A Meaningful Step Forward for Women’s Health
-
Oct 21, 2026, 17:09Chipili Ng’onga: Have You Ever Seen a Result That Just Didn’t Make Sense?
-
Oct 21, 2026, 16:57Fabrice Cognasse: Celebrating the Next Generation of Platelet Research and Transfusion Medicine
-
Oct 21, 2026, 16:47Christabel Odeta: Treating Pediatric Cancer in Children With Sickle Cell Disease
-
Oct 21, 2026, 16:36Sharlene Haywood: Bringing Multidisciplinary Learning Into Nursing Practice